Du är här

2016-02-29

Swedish Orphan Biovitrum AB (publ): Sobi updates outlook for 2016

Swedish Orphan Biovitrum AB (publ)(Sobi(TM)) is updating its outlook for 2016.
Following the positive opinion for Alprolix® received from the Committee for
Medicinal Products for Human Use (CHMP) on Friday 26 February 2016, Sobi
anticipates that the European Commission may grant a Market Authorisation for
the product during Q2 2016.

Sobi now expects total revenues for the full year to be in the range of SEK
4,800 to 5,000 M. Revenues will include one-time credits for Elocta® of SEK
300 to 325 M and for Alprolix of SEK 300 to 325 M, which will not impact
cash. Gross margin is expected be in the range of 68 to 70 per cent.

Sobi will continue to invest in the launches of Elocta and Alprolix, and will
also take on incremental costs of SEK 250 - 300 M reflecting its 50 per cent
share of Biogen's ongoing development costs for the products. Sobi will
assume these costs when it becomes Marketing Authorisation Holder for Elocta
expected in Q1 2016; and for Alprolix in the second half of the year. These
incremental costs are included in this outlook.

Sobi expects EBITA for the full year to be in the range of SEK 1,200 to 1,300
M.

---

About Sobi(TM)

Sobi is an international speciality healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primary
focused on Haemophilia, Inflammation and Genetic diseases. We also market a
portfolio of speciality and rare disease products for partner companies
across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion
(USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed
on NASDAQ OMX Stockholm. More information is available atwww.sobi.com.

For more information please contact

---------------------------------------------------------------------------------------------------------------
| Media relations Investor relations |
| Charlotte af Klercker, Corporate Communications Jörgen Winroth, Vice President, Head of Investor Relations |
|+46 70 729 73 27 +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 |
| charlotte.afklercker@sobi.com jorgen.winroth@sobi.com |
| |
---------------------------------------------------------------------------------------------------------------
The information set out in this press release is announced in accordance with
the Swedish Securities Market Act. The information was submitted for
publication on 29 February 2016 at 08:00 CET.

011e_Updated guidance 2016
http://hugin.info/134557/R/1990035/731039.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire

HUG#1990035

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.